Valganciclovir in patients with glioblastoma

New England Journal of Medicine

Volumn 369, Issue 21, 2013, Pages 2066-2067

  Hellstrand, Kristoffer ^a   Martner, Anna ^a   Bergström, Tomas ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

VALGANCICLOVIR; VIRUS ANTIGEN; VIRUS RNA; ANTIVIRUS AGENT; DRUG DERIVATIVE; GANCICLOVIR;

ANTIGEN EXPRESSION; CYTOMEGALOVIRUS INFECTION; GLIOBLASTOMA; HUMAN; LETTER; PRIORITY JOURNAL; RNA SEQUENCE; SEQUENCE ANALYSIS; ANIMAL; BRAIN TUMOR; NOTE;

ANIMALS; ANTIVIRAL AGENTS; BRAIN NEOPLASMS; GANCICLOVIR; GLIOBLASTOMA; HUMANS;

EID: 84889821569     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1312413     Document Type: Letter

References (4)

1. Söderberg-Nauclér C, Rahbar A, Stragliotto G. Survival in patients with glioblastoma receiving valganciclovir. N Engl J Med 2013;369:985-6.
2. Stragliotto G, Rahbar A, Solberg NW, et al. Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: a randomized, double-blind, hypothesis-generating study. Int J Cancer 2013;133:1204-13.
3. Wrensch M, Weinberg A, Wiencke J, Miike R, Barger G, Kelsey K. Prevalence of antibodies to four herpesviruses among adults with glioma and controls. Am J Epidemiol 2001;154:161-5.
4. Tang KW, Alaei-Mahabadi B, Samuelsson T, Lindh M, Larsson E. The landscape of viral expression and host gene fusion and adaptation in human cancer. Nat Commun 2013;4:2513.